Skip to main content

Advertisement

SpringerLink
Log in

Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease

  • Original Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background/aims

Type 2 diabetic kidney disease (DKD) is frequently accompanied by uncontrollable hypertension due to the sodium sensitivity inherent in DKD and to diuretic-resistant edema. In general, diuretics are effective in treating this condition, but thiazide diuretics are thought to be innocuous in advanced chronic kidney disease (CKD). We examined the renoprotective effects of combination therapy with thiazides and loop diuretics in type 2 DKD patients with CKD stage G4 or G5.

Methods

This study included 11 patients with type 2 DKD and an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 who were suffering from severe edema even with loop diuretics. Each patient received additional hydrochlorothiazide (HCTZ) therapy, which was continued for more than 12 months. We examined clinical parameters including blood pressure (BP), proteinuria, and eGFR before and after the addition of HCTZ.

Results

Patients received a 13.6 ± 3.8 mg/day dose of HCTZ in addition to loop diuretics (azosemide: 120 mg/day in 6 cases, 60 mg/day in 3 cases and furosemide: 80 mg/day in 1 case, 120 mg/day in 1 case). Side effects of HCTZ were not observed in all patients. After the addition of HCTZ therapy, systolic and diastolic blood pressures (S-BP, D-BP) as well as proteinuria significantly decreased (S-BP: at 6 months, p < 0.05 and 12 months, p < 0.01 vs. 0 month, D-BP: at 12 months, p < 0.05 vs. 0 month, proteinuria: at 6 months, p < 0.05 and 12 months, p < 0.01 vs. 0 month). The annual decline in eGFR was not significantly different before and after HCTZ therapy (−7.7 ± 8.5 and −8.4 ± 4.8 mL/min/1.73 m2/year, respectively).

Conclusion

Our findings suggest that the combination of HCTZ and loop diuretics improves BP levels, and decreases proteinuria even in advanced stage type 2 DKD patients with severe edema. The addition of HCTZ therapy was not found to negatively affect the change in eGFR in the present study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, Kimata N, Shigematsu T, Shinoda T, Shoji T, Suzuki K, Taniguchi M, Tsuchida K, Nakamoto H, Nishi H, Hashimoto S, Hasegawa T, Hanafusa N, Hamamoto T, Fujii N, Masakane I, Marubayashi S, Morita O, Yamagata K, Wakai K, Wada A, Watanabe Y, Tsubakihara Y. An overview of regular dialysis treatment in Japan. Ther Apher Dial. 2012;16:483–521.

    Article  PubMed  Google Scholar 

  2. American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care. 2011;34:S11–61.

    Article  PubMed Central  Google Scholar 

  3. Suckling RJ, He FJ, Macgregor GA. Altered dietary salt intake for preventing and treating diabetic kidney disease. Cochrane Database Syst Rev. 2010;. doi:10.1002/14651858.

    PubMed  Google Scholar 

  4. Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Kidney Int. 2004;66:1596–605.

    Article  PubMed  Google Scholar 

  5. Unsal A, Koc Y, Basturk T, Akgun AO, Sakaci T, Ahbap E. Risk factors for progression of renal disease in patient with diabetic nephropathy. Eur Rev Med Pharmacol Sci. 2012;16:878–83.

    CAS  PubMed  Google Scholar 

  6. Zoppini G, Targher G, Chonchol M, Ortada V, Negri C, Stoico V, Bonora E. Predicted of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol. 2012;7:401–8.

    Article  CAS  PubMed  Google Scholar 

  7. Altemtam N, Russell J, Nahas ME. A study of the natural history of diabetic kidney disease (DKD). Nephrol Dial Transplant. 2012;27:1847–54.

    Article  CAS  PubMed  Google Scholar 

  8. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens. 1996;9:342–60.

    Article  CAS  PubMed  Google Scholar 

  9. Dussol B, Moussi-Frances J, Morange S, Somma-Delpero C, Mundler O, Berland Y. A randomized trial of furosemide vs. hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrol Dial Transplant. 2005;20:349–53.

    Article  CAS  PubMed  Google Scholar 

  10. Dussol B, Moussi-Frances J, Morange S, Somma-Delpero C, Mundler O, Berland Y. A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. J Clin Hypertens. 2012;14:32–7.

    Article  Google Scholar 

  11. Japan Nephrology Society. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012. Nihon Jinzo Gakkai Shi. 2012;54:1034–191 (special issue).

    CAS  PubMed  Google Scholar 

  12. Maroni BJ, Steinman TI, Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int. 1985;27:58–65.

    Article  CAS  PubMed  Google Scholar 

  13. Reubi FC, Coottier PT. Effects of reduced glomerular filtration rate on responsiveness to chlorothiazide and mercurial diuretics. Circulation. 1961;23:200–10.

    Article  CAS  PubMed  Google Scholar 

  14. Fujihara CK, Malheiros DMAC, Zatz R. Losartan-hydrochlorothiazide association promotes lasting blood pressure normalization and completely arrests long-term renal injury in the 5/6 ablation model. Am J Physiol Renal Physiol. 2007;292:F1810–8.

    Article  CAS  PubMed  Google Scholar 

  15. Fanelli C, Fernandes BH, Machado FG, Okabe C, Malheiros DM, Fujihara CK, Zatz R. Effects of losartan, in monotherapy or in association with hydrochlorothiazide, in chronic nephropathy resulting from losartan treatment during lactation. Am J Physiol Renal Physiol. 2011;301:F580–7.

    Article  CAS  PubMed  Google Scholar 

  16. O’Grady P, Yee KF, Lins R, Mangold B. Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 1999;48:375–81.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Niemeyer C, Hasenfuss G, Wais U, Knauf H, Schäfer-Korting M, Mutschler E. Pharmacokinetics of hydrochlorothiazide in relation to renal function. Eur J Clin Pharmacol. 1983;24:661–5.

    Article  CAS  PubMed  Google Scholar 

  18. Fliser D. Loop diuretics and thiazides—the case for their combination in chronic renal failure. Nephrol Dial Transplant. 1996;11:408–23.

    Article  CAS  PubMed  Google Scholar 

  19. Abe M, Okada K, Maruyama T, Matsumoto S, Matsumoto K. Blood pressure-lowering and antiproteinuric effect of switching from high-dose angiotensin receptor blockers to normal-dose telmisartan and low-dose hydrochlorothiazide in hypertensive patients with chronic kidney disease. Int J Clin Pharmacol Ther. 2010;48:206–13.

    Article  CAS  PubMed  Google Scholar 

  20. Kobori H, Mori H, Masaki T, Nishiyama A. Angiotensin II blockade and renal protection. Curr Pharm Des. 2013;19:3033–42.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Mancia G, De BG, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De CR, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O’Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, Van ZP, Waeber B, Williams B. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Hypertension. 2007;25:1105–87.

    Article  CAS  Google Scholar 

  22. Arias SC, Valente CP, Machado FG, Fanelli C, Origassa CS, de Brito T, Camara NO, Malheiros DM, Zatz R, Fujihara CK. Regression of albuminuria and hypertension and arrest of severe renal injury by a losartan-hydrochlorothiazide association in a model of very advanced nephropathy. PLoS One. 2013;8:e56215. doi:10.1371/journal.pone.0056215.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Farbakhsh K, Kasiske BL. Dyslipidemia in patients who have chronic kidney disease. Med Clin N Am. 2005;89:689–99.

    Article  PubMed  Google Scholar 

  24. Haaber AB, Kofoed-Enevoldsen A, Jensen T. The prevalence of hypercholesterolaemia and its relationship with albuminuria in insulin-dependent diabetic patients: an epidemiological study. Diabet Med. 1992;9:557–61.

    Article  CAS  PubMed  Google Scholar 

  25. Bakris GL. Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol. 2008;3:S3–10.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl. 2005;99:S87–93.

    Article  CAS  PubMed  Google Scholar 

  27. Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res. 2007;100:342–53.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors have no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma-cho, Omiya-ku, Saitama, Saitama, 330-8503, Japan

    Taro Hoshino, Susumu Ookawara, Haruhisa Miyazawa, Kiyonori Ito, Yuichiro Ueda, Yoshio Kaku, Keiji Hirai, Honami Mori, Izumi Yoshida & Kaoru Tabei

Authors
  1. Taro Hoshino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susumu Ookawara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Haruhisa Miyazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kiyonori Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuichiro Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshio Kaku
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Keiji Hirai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Honami Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Izumi Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kaoru Tabei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susumu Ookawara.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hoshino, T., Ookawara, S., Miyazawa, H. et al. Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease. Clin Exp Nephrol 19, 247–253 (2015). https://doi.org/10.1007/s10157-014-0981-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-014-0981-2

Keywords

Search

Navigation